STOCK TITAN

Nexalin (Nasdaq: NXL) heads to Nasdaq hearing on equity shortfall

(High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Nexalin Technology, Inc. reported that Nasdaq’s Listing Qualifications Staff notified it that stockholders’ equity of $1,519,423 as of June 30, 2026 is below the $2,500,000 minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1. The company also does not meet alternative standards under Rule 5550(b) and previously received a delisting notice for not complying with the minimum bid price requirement and the $5,000,000 initial stockholders’ equity standard. A Nasdaq Hearing Panel is scheduled to consider both deficiencies on September 1, 2026, where the company plans to present its compliance plan. The company notes there is no assurance of a favorable outcome and that delisting could materially reduce liquidity, pressure the market price of its common stock, and hinder capital-raising efforts.

Positive

  • None.

Negative

  • Nasdaq identified a stockholders’ equity shortfall, with equity of $1,519,423 below the $2,500,000 continued listing minimum.
  • The company also faces a minimum bid price deficiency and does not meet the $5,000,000 initial equity requirement, creating multiple bases for potential delisting.
  • Potential delisting from The Nasdaq Capital Market could materially harm liquidity, market price of the common stock, and the company’s ability to raise capital.

Insights

Analyzing...

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice or transferred its listing to a different exchange.
Stockholders’ equity $1,519,423 Reported in the Quarterly Report on Form 10-Q for the period ended June 30, 2026
Minimum stockholders’ equity for continued listing $2,500,000 Nasdaq Listing Rule 5550(b)(1) requirement for The Nasdaq Capital Market
Initial stockholders’ equity requirement $5,000,000 Nasdaq initial listing standard referenced for additional compliance period eligibility
Hearing date September 1, 2026 Scheduled Nasdaq Hearing Panel date to consider listing deficiencies
Par value of common stock $0.001 per share Common Stock, par value $0.001 per share, trading under symbol NXL
Stockholders’ Equity Requirement financial
"the minimum stockholders’ equity requirement of $2,500,000 for continued listing"
A stockholders’ equity requirement is a minimum amount of net assets — assets minus liabilities — that a company must keep on its balance sheet to meet rules set by regulators, lenders or stock exchanges. Think of it as a required safety buffer or minimum bank balance that shows the company has enough of its own capital to absorb losses; falling below it can limit dividends, trigger covenants or risk sanctions, so investors watch it as a sign of financial health and compliance.
Minimum Bid Price Requirement market
"has not regained compliance with the minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(b)(1) regulatory
"for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)"
Nasdaq Hearing Panel regulatory
"requested a hearing before a Nasdaq Hearing Panel to appeal"
A Nasdaq hearing panel is a group of independent reviewers who decide whether a publicly listed company has broken the exchange’s rules and what penalties, if any, should apply. Think of it like a neighborhood committee that reviews complaints and can impose fines, require fixes, or remove a member; for investors, the panel’s rulings can affect whether a stock keeps trading, faces suspension, or suffers reputational and price impact.
delisting market
"serves as an additional basis for delisting the Company’s securities from Nasdaq"
Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

FAQ

What Nasdaq notice did Nexalin Technology (NXL) receive on August 14, 2026?

Nasdaq staff notified Nexalin Technology that its stockholders’ equity of $1,519,423 fell below the $2,500,000 minimum required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1).

What is the stockholders’ equity requirement affecting Nexalin Technology (NXL)?

To remain listed on The Nasdaq Capital Market, Nexalin must maintain stockholders’ equity of at least $2,500,000. Its most recently reported equity was $1,519,423, which Nasdaq staff cited as a continued listing deficiency.

How is Nexalin Technology (NXL) noncompliant with Nasdaq’s minimum bid price rules?

Nexalin previously received a Nasdaq staff determination for not meeting the Minimum Bid Price Requirement under Listing Rule 5550(a)(2) and for not satisfying the $5,000,000 initial stockholders’ equity requirement needed for an additional compliance period.

When is Nexalin Technology’s Nasdaq hearing scheduled and what will be considered?

A Nasdaq Hearing Panel is scheduled for September 1, 2026. The panel will consider both the stockholders’ equity deficiency and the minimum bid price deficiency when deciding whether Nexalin’s common stock may continue listing on The Nasdaq Capital Market.

What could happen to Nexalin Technology (NXL) if Nasdaq delists its common stock?

If delisted from The Nasdaq Capital Market, Nexalin expects a material adverse effect on the liquidity and market price of its common stock and on its ability to raise capital.

Does Nexalin Technology (NXL) plan to address the Nasdaq deficiencies?

Nexalin intends to present its views on the stockholders’ equity deficiency and its plan to regain compliance with the Minimum Bid Price Requirement and Stockholders’ Equity Requirement at the September 1, 2026 Nasdaq hearing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001527352 0001527352 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 14, 2026

 

NEXALIN TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41507   27-5566468
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

1776 Yorktown Street, Suite 550, Houston, Texas   77056
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (832) 260-0222

 

Not Applicable
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   NXL   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

   

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On August 14, 2026, Nexalin Technology, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $1,519,423 reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further notes that the Company does not presently satisfy either of the alternative continued listing standards under Nasdaq Listing Rule 5550(b) (such non-compliance, the “Stockholders’ Equity Deficiency”).

 

As previously disclosed on July 24, 2026, the Company received a Staff Determination letter from Nasdaq (the “Delisting Notice”) stating that the Company has not regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and is not eligible for an additional compliance period under Nasdaq Listing Rule 5810(c)(3)(A) because the Company does not meet the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market (the “Bid Price Deficiency”). The Company timely requested a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal the Bid Price Deficiency, which is currently scheduled for September 1, 2026 (the “Hearing”).

 

The Letter states that the Stockholders’ Equity Deficiency serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Panel will consider the Stockholders’ Equity Deficiency, together with the Bid Price Deficiency, in rendering its determination regarding the Company’s continued listing on The Nasdaq Capital Market. The Company intends to present its views with respect to the Stockholders’ Equity Deficiency at the Hearing, together with its plan to evidence compliance with the Minimum Bid Price Requirement and the Stockholders’ Equity Requirement.

 

There can be no assurance that the Company will be successful in its appeal before the Panel, that the Panel will grant the Company any additional period within which to regain compliance with the Stockholders’ Equity Requirement, the Minimum Bid Price Requirement, or any other applicable Nasdaq continued listing standard, or that, if any such period is granted, the Company will be able to evidence compliance with all applicable Nasdaq continued listing requirements within that period. The Panel has broad discretionary authority under Nasdaq Listing Rules to delist the Company’s securities notwithstanding the Company’s compliance efforts, including based on concerns regarding the Company’s reverse stock split history, financial condition, capital structure, capital-raising activities, or any other factor the Panel deems appropriate. If the Panel determines to delist the Company’s securities, or if the Company is otherwise unable to regain and maintain compliance with the applicable Nasdaq continued listing requirements, the Company’s common stock would be subject to delisting from The Nasdaq Capital Market, which would have a material adverse effect on the liquidity and market price of the Company’s common stock and on the Company’s ability to raise capital.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 17, 2026 NEXALIN TECHNOLOGY, INC.
   
  /s/ Mark White
  Mark White
  Chief Executive Officer

 

2

Filing Exhibits & Attachments

3 documents